1 not yet recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Group 2 - 50 μg dose: new trials by email Literature Review of Group 2 - 50 μg dose trials Research Report on Group 2 - 50 μg dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg - Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus) | Phase 1 | Not yet recruiting | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 90 | 2026-07-01 | 2026-06-10 |
COVID-19 (1) · Severe Acute Respiratory Syndrome (1)
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1)